Evidence map›Paper›PMID 40764668›Full record

ArticleLeukemia2025

Association of the composition of the bone marrow tumor microenvironment in BCR::ABL1-negative myeloproliferative neoplasms with IFN-γ signaling and driver mutations.

Marcus Bauer, Christoforos Vaxevanis, Nadja Jaekel, Hubert Hackl, Andreas Wilfer, Clara Zoellig, Monika Haemmerle, Carsten Müller-Tidow, Haifa Kathrin Al-Ali, Barbara Seliger and 1 more

Abstract read
In one paragraph

Article in Leukemia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Marcus BauerInstitute of Pathology, University Hospital Halle, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.ORCID 0000-0002-0657-6831
Christoforos VaxevanisMedical Faculty, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany.
Nadja JaekelDepartment of Hematology and Oncology, University Hospital Halle, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.ORCID 0000-0001-6162-515X
Hubert HacklInstitute of Bioinformatics, Biocenter, Medical University Innsbruck, Innsbruck, Austria.ORCID 0000-0003-4055-3841
Andreas WilferInstitute of Pathology, University Hospital Halle, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.
Clara ZoelligInstitute of Pathology, University Hospital Halle, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.
Monika HaemmerleInstitute of Pathology, University Hospital Halle, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.
Carsten Müller-TidowDepartment of Hematology Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.ORCID 0000-0002-7166-5232
Haifa Kathrin Al-AliDepartment of Hematology and Oncology, University Hospital Halle, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.ORCID 0000-0001-5009-2239
Barbara Seliger *Medical Faculty, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany. barbara.seliger@uk-halle.de.
Claudia Wickenhauser *Institute of Pathology, University Hospital Halle, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.

Funding

Deutsche Forschungsgemeinschaft (German Research Foundation) SE 581/33-1
6 · The paper itself

Abstract

Constitutive JAK/STAT pathway activation is crucial in the pathogenesis of BCR::ABL1-negative myeloproliferative neoplasms (MPN), but has not yet been linked to interferon (IFN)-γ signaling and tumor microenvironment. Human JAK2 V617F-mutated cell lines, 265 bone marrow biopsies (BMB) of two MPN cohorts, and 50 non-neoplastic BMB, revealed an intrinsic activation of IFN-γ signaling, which was confirmed by public RNA expression data. In vitro analysis of JAK2-mutated cell lines showed an activation of IFN-γ signaling pathway in the absence of IFN-γ in the cell supernatants. In addition, a heterogeneous, but increased expression of IFN-γ signaling components was found in BMB of JAK2-mutated samples with the highest expression in lymphocytes and monocytes, accompanied by increased tumor infiltrating lymphocytes (TIL). Unsupervised clustering identified a prognostic favorable cluster in both patient cohorts characterized by augmented IFN-γ signaling and TILs. This cluster was enriched with JAK2-mutated, JAK-inhibition naive MPN, mainly essential thrombocythemia and polycythemia vera with mild bone marrow fibrosis. Moreover, in silico data confirmed the link between JAK2 mutations and increased IFN-γ signaling. Multivariate Cox regression revealed TILs to be the strongest prognostic marker. In conclusion, JAK2-mutated MPN exhibit an intrinsic activation of IFN-γ signaling associated with changes in the BM TME and patients' outcome. Constitutive activation of the Janus kinases and signal transducer and activator of transcription (JAK/STAT) signaling pathway mainly mediated by mutations in the JAK2, CALR and MPL genes in pluripotent hematopoietic stem cells (HSC) is crucial for the pathogenesis of BCR::ABL1-negative myeloproliferative neoplasms (MPN). Despite the activation of JAK/STAT signaling and its influence on the proliferation of malignant cells is well studied in patient samples and JAK2- and CALR-mutated cell systems, there exists limited information about the link between interferon (IFN)-γ signaling and bone marrow (BM) environment alterations. Therefore, two human JAK2 V617F-mutated cell lines, 265 bone marrow biopsies (BMB) of MPN patients, separated in two independent cohorts, both with known clinical parameters, such as driver mutations, treatment and survival, 50 non-neoplastic BMB and five publicly available bulk and single cell RNA expression data sets of MPN samples with known JAK2 or CALR mutation status were analyzed regarding (i) the role of IFN-γ signaling, (ii) its interrelation with the composition of the local BM tumor microenvironment (TME), (iii) the expression of immune response relevant molecules and (iv) their impact on patients' survival. Created in BioRender. Bauer, M. (2025) https://BioRender.com/h133y7w .

Indexed as

Bone MarrowBone Marrow NeoplasmsFusion Proteins, bcr-ablInterferon-gammaMutationMyeloproliferative DisordersTumor MicroenvironmentAgedFemaleHumansJanus Kinase 2MaleMiddle AgedPrognosisSignal TransductionFusion Proteins, bcr-ablInterferon-gammaJAK2 protein, humanJanus Kinase 2

Identifiers

PMID40764668
PMCPMC12463677

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.